Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01990534 (Clinical Trial/ Brentuximab Vedotin/ SGN-035)

Study Title
A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT01990534)

Trial Description
This phase IV, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin (also known as SGN-035) as a single agent in adult patients with histologically confirmed CD30+ relapsed or refractory classical Hodgkin lymphoma (HL) who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.

This trial is sponsored by Millennium Pharmaceuticals. [1]

Study Data

  • Condition: Lymphoma
  • Interventions:
  • Drugs used in this trial
  • Phase: IV
  • Estimated Enrollment: 60
  • Start: March 2014
  • Estimated Completion: December 2019
  • Last verified: April 2015

Study Schemata

Screen Shot 2016-07-19 at 4.55.53 PM


Last Editorial review: July 21, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

 


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar